Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05031377
Other study ID # ASCVD_OlderAudlts
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 1, 2021
Est. completion date September 1, 2024

Study information

Verified date August 2021
Source The Hong Kong Polytechnic University
Contact Ka Yan Ho, PhD
Phone 27666417
Email kyeva.ho@polyu.edu.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite older adults being exposed to an increased risk of atherosclerotic cardiovascular disease (ASCVD), they are generally underrepresented in cardiovascular prevention programmes. The aim of this study is to assess the feasibility of implementing an integrated exercise and cardiovascular health education programme (HE programme) on older adults at risk of ASCVD.


Description:

The study is a two-arm pilot randomized controlled trial. (1) The control group will receive a basic lifestyle modification talk and governmental education leaflets. (2) The experimental group will receive an integrated exercise and health education programme (HE programme) based on self-efficacy theory. Physical activity level, exercise self-efficacy and ASCVD risk profile including blood pressure, cardiac endurance, and anthropometric outcomes will be investigated via physiological assessments, medical history-taking or questionnaires at baseline, Week 6, and Week 12. Meanwhile, study feasibility will be primarily evaluated in terms of programme acceptability, intervention integrity, recruitment rate and retention rate throughout the process and at Week 12.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date September 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Chinese adults ?60 years old - Having at least one ASCVD risk factor - Pass the cardiovascular fitness evaluation - Able to write and read Chinese, and communicate in Cantonese; - Possess a mobile phone and able to make use of the phone in reading SMS Exclusion Criteria: - Visually impaired, hearing impaired, or suffer from cognitive, psychiatric, or muscular disorder - Having a history of attending similar cardiovascular prevention program - Having a previous history of coronary heart disease or stroke

Study Design


Intervention

Behavioral:
HE programme
Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
Usual care
Participants will receive usual care which primarily includes an education talk on basic health issues. Governmental health education leaflets will be provided for reference.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
The Hong Kong Polytechnic University

Outcome

Type Measure Description Time frame Safety issue
Primary Physical activity level (total score) The physical activity level will be measured by the Chinese Version of Physical Activity Scale for the Elderly (PASE-C). The total score (from zero to 400 or above) is quantified based on frequency values and weights for these activities. The higher the score, the higher the level of physical activity. At baseline, at Week 6, and at Week 12
Primary Physical activity level (classification of physical activity level) The physical activity level will be measured by the Chinese version of International Physical Activity Questionnaire-short form (IPAQ-C-short form). Participants are classified into "inactive", "minimally active" or "health enhancing physical activity (HEPA) active" based on their physical activity levels. At baseline, at Week 6, and at Week 12
Secondary Exercise self-efficacy Exercise self-efficacy will be measured via the Chinese version of Self-Efficacy for Exercise (SEE-C). The total score ranges from 0 to 90. The higher the score, the greater the exercise self-efficacy. At baseline, at Week 6, and at Week 12
Secondary ASCVD risk profiles (Blood pressure, weight, height, BMI & waist circumference, heart rate) The ASCVD risk profiles will be assessed by physical evaluations carried out by blinded, trained outcome assessors. At baseline, at Week 6, and at Week 12
Secondary ASCVD risk profiles (2-minute walk test) 2-minute walk test will be adopted to examine aerobic capacity and self-paced walking capacity by measuring the walking distance covered at two minutes. It will be assessed by blinded, trained outcome assessors. At screening stage, at Week 6, and at Week 12
Secondary Acceptability of the program to participants It will be measured by a self-developed questionnaire At Week 12
Secondary Acceptability of the program to outcome assessors It will be measured by a self-developed questionnaire completed by outcome assessors After the outcome assessors have finished their duties
Secondary Acceptability of the program to lecture deliverers It will be measured by a self-developed questionnaire completed by lecture deliverers After the lecture deliverers have finished their duties
Secondary Adverse events throughout the program Unfavorable or unintended events regarding the programme reported by participants throughout the study period. Throughout the study period
Secondary Program safety evaluated by participants It will be measured via a self-developed questionnaire completed by participants At Week 12
Secondary Eligibility rate The number of eligible potential participants divided by the number of screened people At baseline
Secondary Recruitment rate The percentage of participants who consent to join the study and being recruited At baseline
Secondary Retention rate The percentage of participants remaining in the study At baseline, at Week 6 and at Week 12
Secondary Lecture attendance rate The number of participants in the control group who attend the education talk divided by the number of participants who are randomized into the control group
The number of participants in the experimental group who attend the education session divided by the number of participants who are randomized into the experimental group
The number of participants in the two groups who attend the education session divided by the number of randomized participants
Immediately after education session
Secondary Adherence to intervention The number of participants in the experimental group who practice the tailor-made exercise learned during the intervention divided by the number of participants in the experimental group
Experimental group's frequency in performing tailor-made exercise related to the recommended exercise dosage
At Week 6 and at Week 12
Secondary Attendance rate to data collection The number of participants in the control group who attend the data collection divided by the number of participants who are randomized into the control group
The number of participants in the experimental group who attend the data collection divided by the number of participants who are randomized into the experimental group
The number of participants who attend the data collection divided by the number of randomized participants
At baseline, at Week 6 and at Week 12
Secondary Questionnaire completion rate The number of participants who complete the questionnaire divided by the number of distributed questionnaires At baseline, at Week 6 and at Week 12
Secondary Missing data The percentage of missing data At baseline, at Week 6 and at Week 12
Secondary Structured questionnaire The questionnaire will primarily include patient demographics, medical history, lifestyle patterns, medication use and physical fitness evaluation data, etc. At baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)